×

Equipment and Services Health Care Equipment and Supplies

  • PARIS, Nov 30- France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October. A spokeswoman for the drugs agency said that it had requested further information from the company following the patient's death, which was first reported by Europe 1 radio.

  • Revenue at Medtronic's diabetes unit rose 3 percent to $462 million in the second quarter ended Oct. 28. MiniMed 670 G- the first device that allows a glucose sensor to communicate with an insulin pump and automatically regulate insulin flow- was approved by the U.S. Food and Drug Administration in September and is expected to launch in spring 2017..

  • *Qtrly revenue $7.35 bln vs. est. Sales in its cardiac and vascular unit, where Medtronic sells defibrillators, pacemakers, heart valves and stents, were $2.58 billion in the second quarter ended Oct. 28, below analysts' average estimate of $2.64 billion, compiled by Evercore ISI. MiniMed 670 G was approved by the U.S. Food and Drug Administration in September and is...

  • Nov 22- Medtronic Plc, the world's largest standalone medical device maker, reported a 4 percent rise in quarterly revenue, helped by higher demand for its minimally invasive devices and heart products. The company's net income rose to $1.11 billion, or 80 cents per share, in the second quarter ended Oct. 28 from $520 million, or 36 cents per share, a year earlier.

  • *Kenya, Ghana attract insurers, markets still modest. NAIROBI, Oct 31- Families gather at Nairobi's Garden Square restaurant each evening seeking donations from friends and relatives to meet spiralling medical, school and funeral costs. Changing attitudes and rising disposable incomes in many parts of Africa, from Kenya in the east to Ghana in the west, are...

  • Oct 28- Medical device maker St. Jude Medical Inc said on Friday it has notified doctors to stop implants of one of its cardiac pacemakers, citing reports of problems with electronic data reporting caused by a battery malfunction that could put patients at risk. Jude Chief Medical Officer Mark Carlson said in a statement, adding that the company remains...

  • The company reported a net profit of $228 million, or 17 cents per share, in the third quarter ended Sept. 30. That compared with a loss of $198 million, or 15 cents per share, a year earlier, largely due to litigation charges. Net sales rose to $2.11 billion from $1.89 billion.

  • Oct 25- Edwards Lifesciences Corp on Tuesday reported third quarter sales of its minimally invasive heart valve replacements that fell short of Wall Street estimates, and its previously high-flying shares plunged more than 14 percent. Global transcatheter heart valve therapy sales jumped 38.5 percent to $410.1 million, missing analysts' consensus...

  • Oct 25- Edwards Lifesciences Corp on Tuesday reported third quarter sales of its critically important minimally invasive heart valve replacements that fell short of Wall Street estimates, and its previously high-flying shares plunged nearly 20 percent. Edwards shares, which had been up about 44 percent year-to-date, making it one of the best performers in...

  • FDA SAYS CONTINUES TO' THOROUGHLY ACCESS' ALL CLAIMS OF CYBER VULNERABILITIES IN ST JUDE MEDICAL HEART DEVICES.

  • FDA STATEMENT ADVISES PATIENTS WITH ST JUDE HEART IMPLANTS TO CONTINUE TO USE DEVICES AS DIRECTED BY DOCTORS.

  • NEW YORK, Oct 20- Bullish options on Varian Medical Systems Inc stock saw unusually heavy buying on Thursday before the shares spiked on an unsubstantiated report that General Electric could be in talks with the medical devices company about a possible takeover. Roughly 2,100 Varian Medical Systems call contracts betting on the shares rising above $100 by...

  • Jude by the end of the year and praised the smaller company's handling of claims by short-seller Muddy Waters that its implantable heart devices posed cyber security risks. Shares of Abbott fell 2.7 percent to $40.04 while Alere rose 2.3 percent to $43.36 and St. Jude dipped 0.6 percent to $79, all on the New York Stock Exchange.

  • Jude Medical Inc for $25 billion, reported third-quarter results that nudged past Wall Street estimates, driven by strength in its medical devices business. The company narrowed its adjusted profit from continuing operations forecast to a range of $2.19 to $2.21 per share from $2.14 to $2.24. Abbott reported a net loss from continuing operations of $329...

  • Jude said in a statement that the group, known as the Cyber Security Medical Advisory Board, would provide advice on cyber security standards for medical devices. The FDA launched that probe in August after short-seller Muddy Waters and cyber research firm MedSec Holdings said they had placed bets that St. "We take the cyber security of our devices very...

  • Jude Medical Inc on Tuesday said it would recall some of its 400,000 implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe. All the devices, called ICDs and CRT-Ds, contain batteries that were manufactured before May 23, 2015, when the company added insulation to reduce the chance of an electrical short...

  • Jude Medical Inc on Tuesday said it would recall some of its implanted heart devices due to risk of premature battery depletion, a condition linked to two deaths in Europe. All contain batteries that were manufactured before May 23, 2015, when the company added insulation to reduce the chance of an electrical short circuit. Jude's vice president of quality...

  • Oct 6- Pfizer Inc said on Thursday it would sell its global infusion therapy business to ICU Medical Inc for $1 billion in cash and stock that will give it a major stake in the smaller company. Pfizer had acquired the hospital infusion system business, which has annual sales of about $1.2 billion, through its $15 billion purchase in September 2015 of Hospira, which...

  • Oct 6- Pfizer Inc said on Thursday it would sell its global infusion therapy business, part of its $15 billion Hospira acquisition last year, to ICU Medical Inc for $1 billion in cash and stock. Pfizer had acquired the hospital infusion systems, which have annual sales of about $1.2 billion, through its purchase in September 2015 of Hospira, which sells generic...

  • Oct 6- Medical device maker ICU Medical Inc said it would buy Pfizer Inc's global infusion therapy business, Hospira Infusion Systems, for $1 billion in cash and stock. Pfizer will receive $600 million in cash and nearly $400 million in newly issued shares of ICU Medical common stock, giving the drugmaker a stake of about 16.6 percent. Skadden, Arps, Slate, Meagher&...